Payment overview · 2025
General Payments
$381.36
20 reported records · 8 companies
Healthcare provider profile · identity verified
Michael N Brown, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DILLON, SC · NPI 1497775670
Verified facts
What the public records show
CMS Open Payments records show Michael N Brown, M.D. received $381.36 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Rybelsus, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.43 | 50.5% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.13 | 15.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.88 | 12.0% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.90 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.28 | 4.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.96 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.42 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.36 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.36 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.70 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.73 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.13 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.57 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.88 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 211 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
166 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
211 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
283 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 927 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 745 | 226 |
| Losartan Potassium | Losartan Potassium | 483 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 462 | 149 |
| Metformin Hcl | Metformin Hcl | 402 | 120 |
| Prednisone | Prednisone | 388 | 198 |
| Hydrochlorothiazide | Hydrochlorothiazide | 353 | 98 |
| Omeprazole | Omeprazole | 347 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 82 |
| Gabapentin | Gabapentin | 306 | 95 |
| Jardiance | Empagliflozin | 296 | 65 |
| Furosemide | Furosemide | 294 | 88 |
| Potassium Chloride | Potassium Chloride | 294 | 91 |
| Lisinopril | Lisinopril | 292 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 88 |
| Eliquis | Apixaban | 283 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 68 |
| Alprazolam | Alprazolam | 244 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 234 | 63 |
| Carvedilol | Carvedilol | 224 | 63 |
| Alendronate Sodium | Alendronate Sodium | 213 | 59 |
| Ozempic | Semaglutide | 211 | 37 |
| Metformin Hcl Er | Metformin Hcl | 210 | 60 |
| Sertraline Hcl | Sertraline Hcl | 210 | 63 |
| Cefdinir | Cefdinir | 193 | 131 |
| Tramadol Hcl | Tramadol Hcl | 190 | 45 |
| Allopurinol | Allopurinol | 187 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 61 |
| Azithromycin | Azithromycin | 183 | 120 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 166 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 41 |
| Famotidine | Famotidine | 151 | 46 |
| Pregabalin | Pregabalin | 141 | 24 |
| Meclizine Hcl | Meclizine Hcl | 137 | 45 |
| Simvastatin | Simvastatin | 137 | 40 |
| Donepezil Hcl | Donepezil Hcl | 125 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 34 |
| Mirtazapine | Mirtazapine | 113 | 24 |
| Mounjaro | Tirzepatide | 112 | 18 |
| Amoxicillin | Amoxicillin | 109 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 22 |
| Spironolactone | Spironolactone | 107 | 31 |
| Benazepril Hcl | Benazepril Hcl | 106 | 30 |
| Ezetimibe | Ezetimibe | 104 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 34 |
| Trulicity | Dulaglutide | 103 | 21 |
| Nifedipine Er | Nifedipine | 97 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 68 |
| Finasteride | Finasteride | 94 | 27 |
| Warfarin Sodium | Warfarin Sodium | 93 | 19 |
| Montelukast Sodium | Montelukast Sodium | 88 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 24 |
| Trazodone Hcl | Trazodone Hcl | 80 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 25 |
| Januvia | Sitagliptin Phosphate | 69 | 14 |
| Linzess | Linaclotide | 69 | 26 |
| Farxiga | Dapagliflozin Propanediol | 68 | 13 |
| Glimepiride | Glimepiride | 67 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 16 |
| Xarelto | Rivaroxaban | 65 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 16 |
| Fluconazole | Fluconazole | 58 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 33 |
| Clonazepam | Clonazepam | 55 | 15 |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 21 |
| Levetiracetam | Levetiracetam | 53 | 16 |
| Atenolol | Atenolol | 47 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Nitroglycerin | Nitroglycerin | 44 | 20 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | 13 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 19 |
| Ramipril | Ramipril | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Ofloxacin | Ofloxacin | 28 | 20 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Meloxicam | Meloxicam | 26 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 13 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Captopril | Captopril | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.36 · 20 records | Novo Nordisk Inc | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, GEMTESA, NUPLAZID, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error